H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences on Monday, setting a price target of $50, which is approximately 329.18% above the present share price of $11.65.
Category Press Release
Country United States of America
Companies Featured
atai Life Sciencesatai Life Sciences is one of the biggest companies in the psychedelics field. The company aims to be a platform and has nine subsidiary companies working on everything from psilocybin for depression to DMT administration.